



### PROGRAMME OVERVIEW

update September 11, 2023

December 7, 2023

Venue: CORPUS CONGRESS CENTRE - Oegstgeest  
the Netherlands

## *'Scaling up: through innovations, partnerships and business strategies'*

Dutch Life Sciences conference is Netherlands' most established life sciences event. It has positioned itself as the premier annual meeting place for both Dutch and international players. The event brings together leading CEOs of biotech, pharma and medical devices companies, heads of R&D, academics, and life sciences investors from the healthcare sector for networking opportunities to promote the translation of inventions into e.g. therapies, medical devices and diagnostics distribution in and across the healthcare system. It provides a unique opportunity for discussions, panel presentations and product demonstrations and to meet new companies, paving the way for new business collaborations. The conference will discuss 8 main topics, where 'Scaling up: through innovations, partnerships and business strategies' will be a consistent underlying theme. Our esteemed speakers and thought leaders will explore the latest trends, cutting-edge technologies and disruptive business strategies that are reshaping the life sciences landscape. Together, let's unlock the full potential of scaling up, shaping a healthier and more sustainable future for all.

07:45      **Registration desks open Investors Forum breakfast session**

---

08:00      **Investors forum part 1 - breakfast session -**

hosted by   
INNOVATION

MODERATOR: Dr. ir. Lisanne Blauw, Associate at Thuja Capital (NL)

*The investors forum is an exciting opportunity for those companies looking for equity capital and/or partnerships with companies and institutes across the life sciences value chain, from biotech, medtech and pharma companies to financiers and universities. The forum offers excellent opportunities for presenting your company or university to Venture Capitalists, corporate- and regional investment funds and to discuss your business strategy.*

08:45      **Registration desk, exhibition open**

Registration desk opens for participants of the **Investors Forum breakfast** at **07.45 hours** in the **Penthouse** of CORPUS.

All other participants are welcome as from 08.45 hours in **the Lounge**.



---



09:30-10:50 **Plenary morning programme**


hosted by



- 09:30 **Welcome by moderator Eveline van Rijswijk**  
*Eveline is a science journalist with experience in communicating science on television, radio, online and during events and conferences.*
- 09:35 **Opening**
- 09:45 **Synaffix' journey in creating value for patients through its ADC technology platform and out-licensing business model**  
hosted by   
by Peter van der Sande, CEO Synaffix (NL)
- 10:20 **Venture Challenge**  
hosted by   
*The winner of the Venture Challenge Fall 2023 will be announced!*  
Presentation by Dr.ir. Chrétien Herben, Program Director Life Sciences@Work (NL)
- 10:40 **Break**  
Exhibition open
-



11:30-12:45 **Parallel morning sessions**


<p><b>Women's Health: challenges and opportunities</b></p> <p><i>Hosted by</i></p> <p>Moderator: Prof. dr. Angela Maas</p>	<p>Although one half of the world's population is women, women's health (WH) has been considered a niche market and a subset of healthcare. The current global innovation pipeline reveals mismatches between health investments and health needs. This is starting to shift, leading to new opportunities for investors, companies and other stakeholders across the healthcare ecosystem, resulting in better health outcomes for women. The aim of this session is to give an overview of the latest clinical research and market developments and present the challenges and opportunities in the WH field today.</p>	<p>Presentations by:</p> <ul style="list-style-type: none"> <li>▪ <b>Prof. dr. Angela Maas</b>, Professor in Women's Cardiac Health at RadboudUMC (NL)</li> <li>▪ <b>Ilona Steigerwald MD</b>, Chief Medical Officer at Gedeon Richter Pharma GmbH (DE)</li> <li>▪ <b>Em. Prof. Dr. Herjan J.T. Coelingh Bennink</b>, President Pantarhei Bioscience (NL)</li> </ul>
<p><b>Dealmaking for early-stage Life Sciences companies: licensing, valuations and deal structuring concepts and trends</b></p> <p><i>Hosted by</i></p>  <p>Moderator: Carine van den Brink</p>	<p>Dealmaking play a vital role in driving biopharma innovation forward and delivering life-changing therapies to patients. From the start-up phase were often a license is required from the technology transfer department, partnering with big pharma by out-licensing the technology and financial deals with investors. This session will give insights in the current trends of Life sciences dealmaking such as valuations, out-licensing strategies, R&amp;D partnerships and royalty financing.</p>	<p>Presentations by:</p> <ul style="list-style-type: none"> <li>▪ <b>Nettie Buitelaar</b>, CEO Biotech Booster (NL)</li> </ul>
<p><b>Artificial intelligence and the impact on product development and the product Life Cycle</b></p> <p><i>Hosted by</i></p>  <p>Moderator: Christophe Mombers</p>	<p>2023 has been a year of record spending on artificial intelligence in the pharmaceutical industry. But while drugs, therapeutics and diagnostics of the future may be invented and operated by AI, it also presents challenges in areas such as data collection, regulation and validation. Questions like what are some of the underexplored applications for AI in pharma R&amp;D? And what are the more common AI-related operational issues in R&amp;D? Questions like these along with the regulatory landscape of AI and the validation of AI applications will be discussed during this session.</p>	<p>Presentations by:</p> <ul style="list-style-type: none"> <li>▪ <b>Arunava Ghosh</b>, Quality and Regulatory Compliance Consultant at Progress-Experts in Life Sciences (NL)</li> <li>▪ <b>Stef van Grieken</b>, Co-founder &amp; CEO Cradle (CH)</li> <li>▪ <b>Joren van der Horst</b>, Founder Luo Automation (NL)</li> </ul>

12:45-14:00 **Lunch, networking > exhibition open**

13:00 **Investors forum part 2 - lunch session –**



14:00-15:15 Parallel afternoon sessions

<p><b>Innovation &amp; Regulatory Challenges in Medical Devices</b></p> <p>Hosted by</p>  <p>Moderator: Issam Bouyajrhal</p>	<p>Medical technology continues to develop very rapidly pace and is an area primed for continued development and innovation. We continue to see significant developments in all kinds of technology, like networking speed, artificial intelligence, machine learning, production materials, fiber optic technology, wired and wireless capabilities, and more. Alongside these new advancements also Regulatory changes, like the new Medical Device Regulation creates new challenges for medical device companies. In this session the impact of new technologies like artificial intelligence on the Medical devices will be discussed and how to turn the regulatory needs in your advantage to commercialize innovative products under EU regulations.</p>	<p>Presentations by:</p> <ul style="list-style-type: none"> <li>▪ <b>Anne-Sophie Grell</b>, Regulatory Affairs Manager Medical Device QbD (BE)</li> <li>▪ <b>Pieter De Wilde</b>, Commercial Director Unitron (BE)</li> <li>▪ <b>Wouter Bulten Ph.D.</b>, Chief Innovation Officer at Aiosyn (NL)</li> </ul>
<p><b>Financing life sciences development and growth by M&amp;A, IPO or partnering strategy</b></p> <p>Hosted by</p>  <p>Moderator:</p>	<p>The biotech and MedTech funding environment has undergone significant changes in the last two years. Record-high levels of investment fell drastically, creating more competitive markets that are spurring new approaches and perspectives within emerging biotech. Founders, CEO's and CFO's need to be more creative to find the right financing strategy that facilitates R&amp;D and growth of their company. In this session experienced CFO's and experts will share their insights in the different financing routes like M&amp;A, IPO or a partnering strategy. Is an early M&amp;A path a good option for relatively young companies that are not IPO ready, as expertise and resources will be readily available after acquisition by a bigger company. When to choose for an IPO or how to finance your company by partnerships?</p>	<p>Presentations by:</p> <ul style="list-style-type: none"> <li>▪ <b>Oliver Lade</b>, Senior Manager / Financial Advisory at PwC (NL)</li> </ul>
<p><b>Cell &amp; Gene therapy: Innovations and business strategies</b></p> <p>Hosted by</p>  <p>Moderator:</p>	<p>Continuing advances in cell and gene therapy (CGT) are transforming how biopharma companies treat and potentially cure certain diseases. It is the fastest-growing area of therapeutics, with several new therapies available to patients and hundreds more in development. This session showcases young companies that develop CGT's and an enabling technology. They will talk about their innovations and business strategies for bring bringing their product to the patients.</p>	<p>Presentations by:</p> <ul style="list-style-type: none"> <li>▪ <b>Geert Boink</b>, Founder PacingCure (NL)</li> </ul>





15:15 **Break, networking** > exhibition open

---

16:00 **Wrap up conference**

---

16:05 **Announcement and pitch winner Investors Forum**

---

16:20 **Mibiton Quality Certificate**

Almost twenty-nine years, more than 118 young Life Sciences companies has already been able to accelerate their development, by using a Mibiton investment to purchase state-of-the-art lab facilities or to produce first series of medical devices or agro-food production facilities.

The bi-annual “Mibiton Quality Certificate” will be handed out by **Liduina Hammer**, Chair Mibiton

---

16:30 **Closing keynote presentation: From ‘the boardroom’ to ‘La Cuisine’.**

by Sheila Struyck, Co-founder and Venture Partner SHIFT Invest and Chef on a plant-forward mission.

---

17:05 **End of conference**

**Reception** > exhibition open

---

18:30 **End of the Dutch Life Sciences conference**

*Note: the organisation keeps the right to make changes to the programme at any time.*